NEWS AND EVENTS

Averto Medical, a clinical-stage medical device company pioneering minimally invasive gastrointestinal care, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its ColoSeal™ Intraluminal Colonic Diversion (ICD) System. This designation underscores the potential of ColoSeal™ to significantly improve outcomes for patients undergoing colorectal surgery by eliminating the need for a temporary ostomy.

Cormorant Asset Management leads financing with participation from Venrock Healthcare Capital Partners, LifeSci Venture Partners, CVF, and others; Ken Song, MD joins as Executive Chairman with Dan Puckett and Bihua Chen also joining the Board of Directors